

8. LITERATUR

- (1) Deutsche Dermatologische Gesellschaft. Leitlinie Dermatologie / Psoriasis-Therapie. 8-11-1999.
- (2) Geilen CC, Orfanos CE. Standard and innovative therapy of psoriasis. *Clin Exp Rheumatol.* 2002;20:S81-S87.
- (3) Christophers E. Psoriasis--epidemiology and clinical spectrum. *Clin Exp Dermatol.* 2001;26:314-320.
- (4) Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. *Br J Dermatol.* 2005;152:597-615.
- (5) Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. *Br J Dermatol.* 2005;152:597-615.
- (6) Naldi L. Epidemiology of psoriasis. *Curr Drug Targets Inflamm Allergy.* 2004;3:121-128.
- (7) Tan MH, Lebwohl M. Psoriasis. *Drugs Today (Barc).* 1998;34:641-647.
- (8) Friedrich M, Philipp S, Sabat R, Asadullah K, Sterry W. [Use of biologicals in psoriasis]. *Z Rheumatol.* 2003;62:439-449.
- (9) Schon MP, Boehncke WH. Psoriasis. *N Engl J Med.* 2005;352:1899-1912.
- (10) Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. *Dermatologica.* 1974;148:1-18.
- (11) Augustin M, Berger K, Ehlken B, Zschocke I. Die Psoriasisstherapie in der dermatologischen Praxis führt zu verbesserter Lebensqualität - Ergebnisse einer naturalistischen Multizenter-Studie. *Akt Dermatol.* 2005;31:321-327.
- (12) Andressen C, Henseler T. [Inheritance of psoriasis. Analysis of 2035 family histories]. *Hautarzt.* 1982;33:214-217.
- (13) Oestreicher JL, Walters IB, Kikuchi T et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. *Pharmacogenomics J.* 2001;1:272-287.
- (14) Tomfohrde J, Silverman A, Barnes R et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. *Science.* 1994;264:1141-1145.
- (15) Schon MP, Boehncke WH. Psoriasis. *N Engl J Med.* 2005;352:1899-1912.

- (16) Bowcock AM. The Genetics of Psoriasis and Autoimmunity. *Annu Rev Genomics Hum Genet.* 2005.
- (17) Kumar B, Jain R, Sandhu K, Kaur I, Handa S. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. *Int J Dermatol.* 2004;43:654-658.
- (18) Farber EM, Nall L. Psoriasis in the tropics. Epidemiologic, genetic, clinical, and therapeutic aspects. *Dermatol Clin.* 1994;12:805-816.
- (19) Snellman E, Jansen CT, Lauharanta J, Kolari P. Solar ultraviolet (UV) radiation and UV doses received by patients during four-week climate therapy periods in the Canary Islands. *Photodermatol Photoimmunol Photomed.* 1992;9:40-43.
- (20) Lomholt G. Psoriasis: Prevalence, spontaneous course and genetics. A census study on the prevalence of skin diseases on the Faroe Islands. *G E C Gad.* 1963.
- (21) Kudish AI, Abels D, Harari M. Ultraviolet radiation properties as applied to photoclimate therapy at the Dead Sea. *Int J Dermatol.* 2003;42:359-365.
- (22) Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. *J Am Acad Dermatol.* 1986;15:1007-1022.
- (23) Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. *Am J Clin Dermatol.* 2000;1:159-165.
- (24) Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. *J Am Acad Dermatol.* 1986;15:1007-1022.
- (25) Abel EA. Diagnosis of drug-induced psoriasis. *Semin Dermatol.* 1992;11:269-274.
- (26) Wolf R, Ruocco V. Triggered psoriasis. *Adv Exp Med Biol.* 1999;455:221-225.
- (27) Wolf R. A new concept in the pathogenesis of drug-induced psoriasis. *Med Hypotheses.* 1986;21:277-279.
- (28) Friedrich M, Philipp S, Sabat R, Asadullah K, Sterry W. [Use of biologicals in psoriasis]. *Z Rheumatol.* 2003;62:439-449.
- (29) Schon MP, Boehncke WH. Psoriasis. *N Engl J Med.* 2005;352:1899-1912.
- (30) Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. *J Am Acad Dermatol.* 1985;13:450-456.
- (31) Schon MP, Boehncke WH. Psoriasis. *N Engl J Med.* 2005;352:1899-1912.
- (32) Taylor WJ. Epidemiology of psoriatic arthritis. *Curr Opin Rheumatol.* 2002;14:98-103.
- (33) Deutsche Dermatologische Gesellschaft. Leitlinie Dermatologie / Psoriasis-Therapie. 8-11-1999.
- (34) Deutsche Dermatologische Gesellschaft. Leitlinie Dermatologie / Psoriasis-Therapie. 8-11-1999.

- (35) Deutsche Dermatologische Gesellschaft. Leitlinie Dermatologie / Psoriasis-Therapie. 8-11-1999.
- (36) Tan MH, Lebwohl M. Psoriasis. *Drugs Today (Barc)*. 1998;34:641-647.
- (37) Deutsche Dermatologische Gesellschaft. Leitlinie Dermatologie / Psoriasis-Therapie. 8-11-1999.
- (38) Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. *Clin Exp Dermatol*. 1996;21:399-408.
- (39) Dutz JP, Ho VC. Immunosuppressive agents in dermatology. An update. *Dermatol Clin*. 1998;16:235-251.
- (40) Koo J, Lee J. Cyclosporine: what clinicians need to know. *Dermatol Clin*. 1995;13:897-907.
- (41) Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. *J Dermatolog Treat*. 2004;15:8-13.
- (42) Stiller MJ, Pak GH, Kenny C et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. *J Am Acad Dermatol*. 1992;27:434-438.
- (43) Friedrich M, Sterry W, Klein A et al. Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis. *Acta Derm Venereol*. 2001;81:429-430.
- (44) Raschka C, Koch HJ. Longterm treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. *Hum Exp Toxicol*. 1999;18:738-739.
- (45) Asadullah K, Volk HD, Friedrich M, Sterry W. Experimental therapies for psoriasis. *Arch Immunol Ther Exp (Warsz)*. 2002;50:411-420.
- (46) Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. *Br J Dermatol*. 2004;151 Suppl 69:3-17.
- (47) Friedrich M, Philipp S, Sabat R, Asadullah K, Sterry W. [Use of biologicals in psoriasis]. *Z Rheumatol*. 2003;62:439-449.
- (48) Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. *Trends Immunol*. 2002;23:47-53.
- (49) Asadullah K, Sterry W, Trefzer U. Cytokine therapy in dermatology. *Exp Dermatol*. 2002;11:97-106.

- (50) Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol.* 2002;46:1-23.
- (51) Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. *Arch Dermatol.* 2002;138:657-663.
- (52) Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. *Br J Dermatol.* 2004;151 Suppl 69:3-17.
- (53) Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. *Br J Dermatol.* 2004;151 Suppl 69:3-17.
- (54) Friedrich M, Philipp S, Sabat R, Asadullah K, Sterry W. [Use of biologicals in psoriasis]. *Z Rheumatol.* 2003;62:439-449.
- (55) van de Kerkhof P, Steegers TRPM, Kuipers M, V. Evaluation of topical drug treatment in psoriasis. *Dermatology.* 1998;197:31-36.
- (56) Reed CL, Strunck HC, Steck IE. Other therapeutic applications of vitamin D. *Vitamin D Chemistry, Physiology, Pharmacology, Pathology, Experimental and Clinical Investigations.* 1939;312-313.
- (57) van de Kerkhof P. An update on vitamin D3 analogues in the treatment of psoriasis. *Skin Pharmacol Appl Skin Physiol.* 1998;11:2-10.
- (58) Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. *Med J Osaka Univ.* 1985;35:51-54.
- (59) Berth-Jones J. Maxacalcitol - a new, potent and safe vitamin D analogue for treatment of psoriasis. *Br J Dermatol.* 1999;141:992.
- (60) Baadsgaard O, Traulsen JB, Roed-Petersen J, Bang-Jakobsen H. Tacalcitol for once daily treatment of psoriasis - identification of the optimal concentration. *J Invest Dermatol Symp Proc.* 1996;1:107.
- (61) Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. *Br J Dermatol.* 1993;129:74-76.
- (62) Takahashi H, Ibe M, Kinouchi M et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. *J Dermatol Sci.* 2003;31:21-28.
- (63) Fogh K, Kragballe K. Recent developments in vitamin D analogs. *Curr Pharm Des.* 2000;6:961-972.
- (64) Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. *Br J Dermatol.* 1988;119:223-230.
- (65) Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). *Arch Dermatol.* 1989;125:1647-1652.

- (66) Kragballe K, Gjertsen BT, De Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. *Lancet*. 1991;337:193-196.
- (67) Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. *J Am Acad Dermatol*. 1992;26:736-743.
- (68) Berth-Jones J, Chu AC, Dodd WA et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. *Br J Dermatol*. 1992;127:266-271.
- (69) Dwyer C, Chapman RS. Calcipotriol and hypercalcaemia. *Lancet*. 1991;338:764-765.
- (70) Bower M, Colston KW, Stein RC et al. Topical calcipotriol treatment in advanced breast cancer. *Lancet*. 1991;337:701-702.
- (71) Russell S, Young MJ. Hypercalcaemia during treatment of psoriasis with calcipotriol. *Br J Dermatol*. 1994;130:795-796.
- (72) Lange L. Konzepte in der Humanpharmakologie. In: Jaeger H, Seifert W, Klingmann J, eds. *Good Clinical Practice I+II*. Berlin, Heidelberg: Springer Verlag; 1992:49-52.
- (73) *Federal Register*. Vol.62, No. 90, 25691-25709. 9-5-1997.
- (74) Gehan EA, George SL. Estimation of human body surface area from height and weight. *Cancer Chemother Rep*. 1970;54:225-235.
- (75) Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. *CUTIS*. 2000;66:4-11.
- (76) Nola I, Kostovic K, Kotrulja L, Lugovic L. The use of emollients as sophisticated therapy in dermatology. *Acta Dermatovenerol Croat*. 2003;11:80-87.